Neuroscience
A report from FierceBiotech:
Roche provides update on leading late-stage pharmaceutical pipeline
New data on medicines with the potential to redefine standard of care highlighted at Investor event
Posted December 9, 2010
"Roche (SIX: RO, ROG; OTCQX: RHHBY) today will provide an update on its leading late-stage pipeline comprising twelve new molecular entities in key therapeutic areas. The London investor event will focus on major progress that has been achieved in recent months with Roche's late-stage pipeline assets in the areas of oncology and CNS, as well as on further development plans of these potential breakthrough medicines."
read the full report
- Cns Drug Development
A short but informative blogpost earlier today from the blog, In The Pipeline:CNS Drug Development Claims Another Victim Read the post...
- From The In The Pipeline Blog: Novartis And Neuroscience
Read the In The Pipeline blog entry (06 December 2011)....
- Alzheimer's: The Current Pipeline
FierceBiotechResearch has an article which presents a very brief overview of the current Alzheimer's disease drug pipeline: It is available at the link below: Making sense of the Alzheimer's drug pipeline FierceBiotechResearch March 15, 2011 —...
- Neurodegenerative Disease Drug Discovery: Ucsf And Genentech
From Fierce Biotech: UCSF enters drug discovery agreement with Genentech Posted February 19, 2010 "The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover...
- Business World: Astrazeneca, Renovis - Cerovive (nxy-059) In Stroke Treatment
From TheStreet.com:AstraZeneca's Results Boost Tiny Renovis By Robert Steyer TheStreet.com Staff Reporter 5/4/2005 1:03 PM EDT AstraZeneca (AZN :NYSE - commentary -research ) reported mixed results for a late-stage clinical trial of an experimental...
Neuroscience
Roche Pipeline Report
A report from FierceBiotech:
Roche provides update on leading late-stage pharmaceutical pipeline
New data on medicines with the potential to redefine standard of care highlighted at Investor event
Posted December 9, 2010
"Roche (SIX: RO, ROG; OTCQX: RHHBY) today will provide an update on its leading late-stage pipeline comprising twelve new molecular entities in key therapeutic areas. The London investor event will focus on major progress that has been achieved in recent months with Roche's late-stage pipeline assets in the areas of oncology and CNS, as well as on further development plans of these potential breakthrough medicines."
read the full report
- Cns Drug Development
A short but informative blogpost earlier today from the blog, In The Pipeline:CNS Drug Development Claims Another Victim Read the post...
- From The In The Pipeline Blog: Novartis And Neuroscience
Read the In The Pipeline blog entry (06 December 2011)....
- Alzheimer's: The Current Pipeline
FierceBiotechResearch has an article which presents a very brief overview of the current Alzheimer's disease drug pipeline: It is available at the link below: Making sense of the Alzheimer's drug pipeline FierceBiotechResearch March 15, 2011 —...
- Neurodegenerative Disease Drug Discovery: Ucsf And Genentech
From Fierce Biotech: UCSF enters drug discovery agreement with Genentech Posted February 19, 2010 "The University of California, San Francisco has signed a partnership agreement with Genentech, Inc., a wholly owned member of the Roche Group, to discover...
- Business World: Astrazeneca, Renovis - Cerovive (nxy-059) In Stroke Treatment
From TheStreet.com:AstraZeneca's Results Boost Tiny Renovis By Robert Steyer TheStreet.com Staff Reporter 5/4/2005 1:03 PM EDT AstraZeneca (AZN :NYSE - commentary -research ) reported mixed results for a late-stage clinical trial of an experimental...